IMCR vs. GRFS, TGTX, NUVL, LNTH, TLX, AXSM, AKRO, ADMA, PCVX, and KRYS
Should you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), ADMA Biologics (ADMA), Vaxcyte (PCVX), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.
Immunocore vs. Its Competitors
Grifols (NASDAQ:GRFS) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.
In the previous week, Immunocore had 1 more articles in the media than Grifols. MarketBeat recorded 2 mentions for Immunocore and 1 mentions for Grifols. Immunocore's average media sentiment score of 0.58 beat Grifols' score of -0.13 indicating that Immunocore is being referred to more favorably in the news media.
84.5% of Immunocore shares are owned by institutional investors. 0.2% of Grifols shares are owned by insiders. Comparatively, 10.4% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Grifols has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.
Grifols currently has a consensus target price of $10.30, indicating a potential upside of 13.50%. Immunocore has a consensus target price of $58.89, indicating a potential upside of 78.40%. Given Immunocore's higher possible upside, analysts clearly believe Immunocore is more favorable than Grifols.
Grifols has a net margin of 0.00% compared to Immunocore's net margin of -6.48%. Grifols' return on equity of 0.00% beat Immunocore's return on equity.
Grifols has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.
Summary
Grifols beats Immunocore on 9 of the 17 factors compared between the two stocks.
Get Immunocore News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunocore Competitors List
Related Companies and Tools
This page (NASDAQ:IMCR) was last updated on 7/6/2025 by MarketBeat.com Staff
